Accumulation of uPA - PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer

British Journal of Cancer

Volumn 88, Issue 1, 2003, Pages 96-101

  Schneider, J ^a,b,e   Pollan M ^c   Tejerina, A ^a   Sanchez J ^a,d   Lucas, A R ^a  

^a Fund Tejerina Ctro Patol Mama   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e Breast Pathology Center   (Spain)

Author keywords

Axillary nodes; Early breast cancer; Metastasis; PAI 1; UPA

Indexed keywords

KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN P53; UROKINASE;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; EARLY CANCER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

AXILLA; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037434428     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600656     Document Type: Article

References (14)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
2. Cederholm-Williams SA, Houlbrook S, Porter NW, Marshall JM, Chissic H (1985) Characterisation of plasminogen activators secreted by human malignant cells. In Treatment of Metastasis: Problems and Prospects, Hellmann K, Eccles SA (eds) pp 347-350. London: Taylor & Francis
3. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G (2002) Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 160: 237-246
4. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jänicke F, Meijer-van Gelder ME, Henzen-Longmans SC, van Putten WL, Klijn JG (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643
5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
6. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Hofler H, Jänicke F, Graeff H, Schmitt M (1999) Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up for primary breast cancer and following first relapse. Breast Cancer Res Treat 54: 147-157
7. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920
8. Lockwood CJ (2001) Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells. Am J Obstet Gynecol 184: 798-804
9. Olson D, Pollanen J, Hoyer-Hansen G, Ronne E, Sakaguchi K, Wun TC, Appella E, Danø K, Blasi F (1992) Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129-9133
10. Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N (2000) The complex between urokinase and its Type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 60: 6927-6934
11. Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H (1991) Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50: 731-741
12. Schneider J, Pollan M, Jimenez E, Ruibal A, Lucas AR, Nuñez MI, Sanchez J, Tejerina A (1999) Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer. Tumor Biol 20: 319-330
13. Schneider J, Lucas R, Sanchez J, Tejerina A, Ruibal A (2000) Cellular accumulation of uPA - PAI-1 and uPA - PAI-2 complexes in early (pT1) breast cancer: a new link in the uPA - uPAr-PAI chain. In Vivo 14: 507-512
14. Sten-Lindner M, Seddighzadeh M, Engel G, Rutqvist LE, Linder S, Skoog L, Wiman B (2001) Prognostic importance of the uPA/PAI-1 complex in breast cancer. Anticancer Res 21: 2861-2866